Search results
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of…
View more
Added:
1 year ago
In this expert clinical discussion, join Prof Victoria Delgado as she discusses her manuscript on multimodality imaging approaches in hypertrophic cardiomyopathy (HCM). Dr Clara Saldarriaga, Guest Editor of the HCM special focus collection, facilitates this in-depth conversation exploring how different imaging techniques enhance diagnosis, phenotyping, and risk stratification in HCM patients.The…
View more
Added:
8 months ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Added:
1 year ago
AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).Dr Sanjiv Shah (Bluhm Cardiovascular Institute, Chicago, US) joins us onsite at AHA Conference to discuss the…
View more
Added:
1 year ago
HRS 2025 - Contemporary outcomes from implantable devices in non-ischemic cardiomyopathy patients observed more advanced heart failure symptoms in women at the time of ICD implantation, and white women implanted with CRT-D devices had significantly lower ventricular arrhythmia events compared to men of all races and black women implanted with both device types.Dr Valentina Kutyifa (University of…
View more
Added:
1 year ago
Guest Editor Dr Vijay Chopra discusses the motivation behind the newly curated Special Focus on mineralocorticoid receptor antagonists.Dr Chopra explores why this topic is more relevant than ever, particularly as the field moves beyond traditional aldosterone antagonists toward novel agents like finerenone and aldosterone synthase inhibitors.From addressing hyperkalaemia fears to identifying gaps…
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Dr Paul Stevens discusses 2024 KDIGO guideline updates.
View more
Added:
1 year ago
Intra-operative 4-chamber transesophageal echo (TEE) view: Intraoperative TEE in 4-chamber view showing a highly mobile mass with near cavity obliteration of the LA.
View more